Clinical Trials Browser

Phase 2 × berzosertib × Clear all

NCT03896503 2026-03-19

Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

Phase 2 Active not recruiting

104 enrolled 22 charts

Small Cell Lung Carcinoma

NCT02595892 2026-03-18

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Active not recruiting

70 enrolled 23 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03517969 2025-10-20

M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

73 enrolled 14 charts

Prostatic Neoplasms

NCT02567409 2025-03-03

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

Phase 2 Completed

87 enrolled 13 charts

Metastatic Bladder Urothelial Carcinoma

NCT04768296 2024-09-26

Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)

Phase 2 Completed

76 enrolled 42 charts

Hereditary Sensory and Autonomic Neuropathies, Small Cell Lung Carcinoma

NCT03718091 2023-07-07

M6620 (VX-970) in Selected Solid Tumors

Phase 2 Completed

30 enrolled 15 charts

Leiomyosarcoma, Osteosarcoma